116 related articles for article (PubMed ID: 20632523)
1. The Manitoba human papillomavirus vaccine surveillance and evaluation system.
Kliewer EV; Demers AA; Brisson M; Severini A; Lotocki R; Elias B; Hammond G; Wurtak G;
Health Rep; 2010 Jun; 21(2):37-42. PubMed ID: 20632523
[TBL] [Abstract][Full Text] [Related]
2. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.
Pomfret TC; Gagnon JM; Gilchrist AT
J Clin Pharm Ther; 2011 Feb; 36(1):1-9. PubMed ID: 21198715
[TBL] [Abstract][Full Text] [Related]
4. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
Villa LL
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus vaccination and Pap testing profile in Manitoba, Canada.
Kliewer EV; Mahmud SM; Demers AA; Lambert P
Vaccine; 2013 Dec; 32(1):33-8. PubMed ID: 24211170
[TBL] [Abstract][Full Text] [Related]
6. Correlating immunity with protection for HPV infection.
Frazer I
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
[TBL] [Abstract][Full Text] [Related]
7. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
Khaliq SA; Shyum Naqvi SB; Fatima A
Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
[TBL] [Abstract][Full Text] [Related]
8. Post-licensure monitoring of HPV vaccine in the United States.
Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF
Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia.
Shi JF; Qiao YL; Smith JS; Dondog B; Bao YP; Dai M; Clifford GM; Franceschi S
Vaccine; 2008 Aug; 26 Suppl 12():M53-9. PubMed ID: 18945414
[TBL] [Abstract][Full Text] [Related]
10. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
11. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Arbyn M; Dillner J
J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
[TBL] [Abstract][Full Text] [Related]
12. Adolescent and young adult HPV vaccination in Australia: achievements and challenges.
Garland SM; Skinner SR; Brotherton JM
Prev Med; 2011 Oct; 53 Suppl 1():S29-35. PubMed ID: 21962468
[TBL] [Abstract][Full Text] [Related]
13. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.
Bonanni P; Cohet C; Kjaer SK; Latham NB; Lambert PH; Reisinger K; Haupt RM
Vaccine; 2010 Jul; 28(30):4719-30. PubMed ID: 20451636
[TBL] [Abstract][Full Text] [Related]
14. GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side.
Shi L; Sings HL; Bryan JT; Wang B; Wang Y; Mach H; Kosinski M; Washabaugh MW; Sitrin R; Barr E
Clin Pharmacol Ther; 2007 Feb; 81(2):259-64. PubMed ID: 17259949
[TBL] [Abstract][Full Text] [Related]
15. [Value of general human papillomavirus vaccination in sexually active women].
Hampl M
Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S95-9. PubMed ID: 19353480
[TBL] [Abstract][Full Text] [Related]
16. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
Barr E; Gause CK; Bautista OM; Railkar RA; Lupinacci LC; Insinga RP; Sings HL; Haupt RM
Am J Obstet Gynecol; 2008 Mar; 198(3):261.e1-11. PubMed ID: 18313445
[TBL] [Abstract][Full Text] [Related]
17. Impact of prophylactic human papillomavirus vaccines on dermatology and venereology.
Gross G
G Ital Dermatol Venereol; 2008 Aug; 143(4):259-65. PubMed ID: 18833082
[TBL] [Abstract][Full Text] [Related]
18. Practical implementation of HPV vaccines in clinical practice.
Kimmel SR
J Fam Pract; 2006 Nov; Suppl():18-22. PubMed ID: 17366754
[TBL] [Abstract][Full Text] [Related]
19. From desire to disease: human papillomavirus (HPV) and the medicalization of nascent female sexuality.
Polzer JC; Knabe SM
J Sex Res; 2012; 49(4):344-52. PubMed ID: 22720826
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus (HPV) vaccines: a Canadian update.
Foerster V; Murtagh J
Issues Emerg Health Technol; 2007 Dec; (109):1-8. PubMed ID: 18062141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
